首页> 美国卫生研究院文献>Bone Research >Ankylosing spondylitis: etiology pathogenesis and treatments
【2h】

Ankylosing spondylitis: etiology pathogenesis and treatments

机译:强直性脊柱炎:病因发病机制和治疗方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ankylosing spondylitis (AS), a common type of spondyloarthropathy, is a chronic inflammatory autoimmune disease that mainly affects spine joints, causing severe, chronic pain; additionally, in more advanced cases, it can cause spine fusion. Significant progress in its pathophysiology and treatment has been achieved in the last decade. Immune cells and innate cytokines have been suggested to be crucial in the pathogenesis of AS, especially human leukocyte antigen (HLA)‑B27 and the interleukin‑23/17 axis. However, the pathogenesis of AS remains unclear. The current study reviewed the etiology and pathogenesis of AS, including genome-wide association studies and cytokine pathways. This study also summarized the current pharmaceutical and surgical treatment with a discussion of future potential therapies.
机译:强直性脊柱炎(AS)是一种常见的脊椎关节炎,是一种慢性炎性自身免疫性疾病,主要影响脊柱关节,引起严重的慢性疼痛。此外,在更高级的情况下,它可能导致脊柱融合。在过去的十年中,其病理生理学和治疗取得了重大进展。有人提出免疫细胞和先天性细胞因子在AS的发病过程中至关重要,尤其是人白细胞抗原(HLA)‑B27和白介素23/17轴。然而,AS的发病机制仍不清楚。本研究回顾了AS的病因和发病机制,包括全基因组关联研究和细胞因子途径。这项研究还总结了当前的药物和外科治疗方法,并讨论了未来的潜在疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号